Introduction {#sec1-1}
============

The incidence of thyroid disorders in India is high, with hypothyroidism being a condition that is not adequately controlled in the country at present. Lack of thyroid hormone or resistance of the body tissue to thyroid hormone with respect to metabolic demand results in disorder called hypothyroidism. Thyroid hormone is required for the normal functioning of each and every tissue of the body. Hence, its deficiency manifests as multisystem involvement. It is estimated that about 42 million people suffer from thyroid disorders in India, of which hypothyroidism is most common with a prevalence of 5.4%.\[[@ref1]\] The modern system of medicine is still exploring medicine for better and more effective management of hypothyroidism. Synthetic thyroid hormone derivatives may bring the value of thyroid-stimulating hormone (TSH) and T~4~ to normal range, but the increased dosage and continuous medicine make the patient drug dependent till the end of the life. Even after years of treatment, it is associated with failure to provide relief in clinical manifestations. Moreover, excessive thyroid hormone replacement carries the potential for serious long-term metabolic complications (e.g., accelerated osteoporosis).\[[@ref2]\]

The major function of the thyroid gland is to act as a spark for the maintenance of oxidative metabolism in most tissues. In Ayurveda parlance, this is attributed as the function of *Agni* (system related to metabolism). As far as the management of hypothyroidism through Ayurveda is concerned, hormonal replacement is not possible through drugs. However, one can interpret the pathogenesis of hypothyroidism in the context of Ayurveda, in which role of *Agni* is foremost and through its management, wholesome normal activity of the thyroid gland may be achieved. The objective of treatment should be to address the problem at its root by regulating the immune system and decreasing inflammation. *Srotoshodhana* (cleansing of the macro and microchannels), *Agnideepana* (stimulation of the digestion and metabolism), *Pachana* (digestion) and *Vatanulomana* (proper regulation of excretory system) are the main principles of treatment.

The trial drug *Punarnavadi Kashayam*\[[@ref3]\] is mentioned in *Chakradatta* for the management of *Shotha* (*odema*), which is one of the common manifestations of hypothyroidism. It contains *Punarnava*, *Devadaru* and *Shunthi* along with *Guggulu. Triphladya Guggulu*\[[@ref4]\] is cited in *Yogaratnakara* for the management of *Gandamala*. It contains *Guggulu* in combination with *Trikatu*, *Triphala* and *Kanchanara*. The drug possesses *Deepana*-*Pachana Dravya* along with *Kanchanara*, which is widely being practiced for the management of hypothyroidism. Thus, keeping in mind the possible effects of trial drugs in normalizing the impaired *Agni*, they were selected to evaluate their efficacy in the management of hypothyroidism.

Materials and Methods {#sec1-2}
=====================

Selection of patients {#sec2-1}
---------------------

A total of 15 patients suffering from hypothyroidism were selected from outdoor patient department and indoor patient department of Panchakarma, IPGT & RA, Jamnagar, irrespective of their sex, religion, caste, occupation etc.

Ethical clearance was obtained from the Institutional ethics committee vide PGT/7-A/Ethics/2015-2016/1490/2.42 dated August 25, 2015. This study is registered in Clinical Trial Registry of India with registration no. CTRI/2016/10/007378. Informed written consent in language suitable to the patients was obtained from all enrolled participants.

Inclusion criteria {#sec2-2}
------------------

Diagnosed cases of hypothyroidism on the basis of serum TSH, T~3~ and T~4~ levels.Patient's serum TSH level \>4.5 μIU/ml\[[@ref5]\]Total serum T~4~ level less than normal value (total serum T~4~ = 4.5--12.5 mg/dl)Total serum T~3~ level less than normal value (total serum T~3~ = 80--220 ng/dl).Patients having clinical features of hypothyroidism:Puffiness of the face and eyelidsPeripheral edemaDry coarse skinBreathlessnessConstipationWeaknessLethargyFatigueMuscle acheMenstrual abnormalityHair lossAge 20--60 years.

Exclusion criteria {#sec2-3}
------------------

Patients with ischemic heart disease, uncontrolled hypertension, myocardial infarction, cerebrovascular event, cardiac arrhythmias, pregnancy and active malignant disease were excluded from the study.

Laboratory investigations {#sec2-4}
-------------------------

Routine hematological (complete blood count and erythrocyte sedimentation rate) investigation.Thyroid profile (serum T~3~, serum T~4~, serum TSH)Lipid profile (serum cholesterol, serum triglyceride, serum low-density lipoproteins, serum very LDL, serum high-density lipoprotein). These investigations were carried out before and after the treatment.

Methodology {#sec2-5}
-----------

All the patients were advised to discontinue any drug they might be taking for the management of hypothyroidism to assess the unbiased effect of therapies. The drug was withdrawn 1 week before including the patient in the clinical trial.

All the patients were advised to take meal only upon hungry, green gram predominant diet, to avoid full stomach diet and to refrain from dairy products or heavy to digest food articles. Patients were strictly advised to abstinate from day sleep during the trial period.

Drugs and dosage {#sec2-6}
----------------

*Triphladya Guggulu* 2 *Vati* twice daily (each *Vati* weighing 500 mg) with lukewarm water after meal*Punarnavadi* decoction 30 ml twice a day before meal.

The trial drugs were procured from Pharmacy, Gujarat Ayurved University. Ingredients of the same are mentioned in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

###### 

Ingredients of *Triphaladya Guggulu*
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###### 

Ingredients of *Punarnavadi Kashaya*
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Preparation method of trial drugs {#sec2-7}
---------------------------------

### Triphladya Guggulu {#sec3-1}

*T. Guggulu* was prepared by dissolving *Triphala* purified *Guggulu* in *Kanchanara* bark decoction until it attained a sticky consistency, followed by addition of powders of *Trikatu* and *Triphala* along with quantity sufficient honey for making pills of 500 mg size.

### Preparation of Punarnavadi Kashayam {#sec3-2}

Patients were advised to boil 15 g of coarse powder of *Punarnavadi Yavakuta* in eight parts of water and reduce it to one-fourth over mild heat and to consume it empty stomach twice daily.

The trial drugs were administered for 45 days.

### Follow-up study {#sec3-3}

After completion of the therapy, patients were followed for 1 month.

Criteria for assessment {#sec2-8}
-----------------------

Improvement observed in patients was assessed mainly on the basis of relief in percentage change in the presenting complaints of hypothyroidism on the basis of scoring pattern decided in a previous study \[[Table 3](#T3){ref-type="table"}\]\[[@ref5]\]Thyroid profile (Serum TSH, T~3~ and T~4~).

###### 

a-l: Grading criteria
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Statistical analysis {#sec2-9}
--------------------

The data obtained in the study were subjected to statistical analysis to evaluate the significance of curative effect of therapies.

Subjective criteria {#sec2-10}
-------------------

Percentage of improvement in each parameter was calculated. Wilcoxon's signed-rank test was applied to the data to analyze the effect of therapy on subjective parameters.

Objective criteria {#sec2-11}
------------------

Obtained data of objective parameters were subjected to student's paired *t*-test to analyze the effect of therapy on objective parameters.

The results were interpreted at *P* \< 0.05, *P* \< 0.01 and *P* \< 0.001 significance levels.

Observations {#sec2-12}
------------

Out of the 15 registered patients, maximum patients belonged to age group of 31--40 years (60%) and majority of the participants were female (93.34%). History of hypertension was reported in 93.34% of the patients. Family history of hypothyroidism was positive in 40% of the patients. Chronicity more than 5 years was reported in 40% of the patients. *Samashana* (taking wholesome and unwholesome food together) and *Adhyashana* (eating in spite of indigestion) were practiced by 80% and 53.34% of the patients, respectively. *Lavana Rasa* (salty), *Madhura Rasa* (sweet), *Katu Rasa* (pungent taste) and *Amla Rasa* (sour) predominant diet were reported being consumed by 100%, 93.34%, 93.34% and 66.67% of the patients, respectively. Nearly 100% of the patients had the habit of holding their natural urges (*Vegasandharana*). About 86.67% of the patients reported *Avyayama* (lack of exercise). *Divaswapna* (day sleep) was practiced by 73.34% of the patients. *Atichintana* (over worry) was found in 73.34% of the patients. *Mandagni* (weak digestive system) was observed in 60% of the patients. About 66.67% of the patients had *Krura Koshtha* (costive bowel). Symptoms of vitiation of *Rasavaha* and *Medovaha Srotasa* were observed in 100% of the patients followed by *Annavaha Srotodushti* in 93.33% of the cases.

Results {#sec1-3}
=======

Effect of therapy on presenting complaints of hypothyroidism {#sec2-13}
------------------------------------------------------------

The results were significant in almost all the signs and symptoms of hypothyroidism. Highly significant improvement (*P* \< 0.001) was observed in weakness, fatigue and muscle ache and the results were statistically significant (*P* \< 0.01) on all the other complaints such as puffiness over the face and eyelids, peripheral edema and dry coarse skin \[[Table 4](#T4){ref-type="table"}\].

###### 

Effect of therapy on chief complaints using Wilcoxon's signed-rank test
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Effect of therapy on weight and body mass index {#sec2-14}
-----------------------------------------------

There was a significant decrease (*P* \< 0.01) in weight and body mass index by 3.14% and 3.20%, respectively \[[Table 5](#T5){ref-type="table"}\].

###### 

Effect of therapy on weight and body mass index
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Effect of therapy on thyroid profile {#sec2-15}
------------------------------------

Serum TSH was insignificantly elevated (*P* \> 0.05) by 40.66%, serum T~3~ was insignificantly decreased (*P* \> 0.05) by 6.78%, and an increase of 7.95% in serum T~4~ was observed which was statistically insignificant \[[Table 6](#T6){ref-type="table"}\].

###### 

Effect of therapy on thyroid profile
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Effect of therapy on hematological parameters and lipid profile {#sec2-16}
---------------------------------------------------------------

There was statistically insignificant change (*P* \> 0.05) in all the hematological parameters and lipid profile.

Overall effect of therapy {#sec2-17}
-------------------------

Excellent improvement was found in 33.33% of the patients 53.33% of the patients showed marked improvement, 6.66% of the patients showed moderate improvement and same percentage that is 6.66% of the patients showed mild improvement. None of the patients remained unchanged \[[Table 7](#T7){ref-type="table"}\].

###### 

Overall effect of therapy
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Discussion {#sec1-4}
==========

In most cases of hypothyroidism, a specific cause is not apparent. It is believed that hypothyroidism is usually secondary to an autoimmune reaction.\[[@ref6]\] In autoimmune disorders, the immune system cells do not recognize the cell as "self" and mount an immune response against them. This self-attack by the immune system increases inflammation and inflammation has a profound effect on all aspects of thyroid metabolism and physiology. Pro-inflammatory cytokines can inhibit type 2 5'- deiodinase enzyme activity which is required for the conversion of T~4~ to T~3~.\[[@ref7]\] Inflammation causes elevated cortisol levels, leading to a decrease in TSH and lowered thyroid hormone production. Cortisol also inhibits the conversion of T~4~ to active T~3~ and increases the conversion of T~4~ to reverse T~3~.\[[@ref8]\] Thyroid hormones stimulate diverse metabolic activities in most tissues, leading to an increase in basal metabolic rate. By way of analogy, the action of thyroid hormones is akin to *Agni*. The cause of disease, that is, impaired metabolism can be compared with *Agnimandya*.

Discussion on effect of therapy on thyroid profile {#sec2-18}
--------------------------------------------------

Out of 15 patients in the present trial, 10 patients had encouraging results in thyroid profile, not much change in thyroid profile was observed in 2 patients but the result worsened in 3 patients. On retrospective analysis, it was observed that patients whose thyroid profile had worsened during the trial had *Vata-Kapha Prakriti*, which can make the disease condition difficult to treat, due to the *Vata-Kapha* predominance in disease. Chronicity in those cases was reported to be more than 5 years. All of them had positive history for intake of levothyroxine. Chronicity and past treatment history can also be considered as one of the factors for negative results. Stress was a common factor in all these patients. One of these patients was a case of hypothyroidism caused after the treatment for Grave's disease and in patients who develop hypothyroidism after the treatment of Graves' disease, there is often an underlying autonomous function, necessitating lower replacement dose. This might be the reason why thyroid function worsened in this patient. The half-life elimination of thyroxine (T4) in hypothyroid patients is 9--10 days.\[[@ref9]\] Half-life (abbreviated t~½~) is the time required for a quantity to reduce to half its initial value, but the washout period in the present trial was 7 days, this reflects that before treatment thyroid profile was under the influence of levothyroxine, whereas after treatment, the change in thyroid profile was solely under the influence of trial interventions.

Recovery of the hypothalamic--pituitary axis usually requires 8 weeks at which time the TSH and free T~4~ levels can be measured,\[[@ref10]\] that is, TSH responses are gradual and should be measured about 2 months after instituting treatment.\[[@ref11]\] However, the duration of the trial was limited to 6 weeks. Despite the short duration of the clinical trial, positive changes were observed in thyroid profile in 10 of 15 patients.

Thus, from the above observations, it can be inferred that both the trial drugs were helpful in normalizing the thyroid function, but better results could have been possible if the duration of trial was longer.

Mode of action of trial drugs {#sec2-19}
-----------------------------

In hypothyroidism, etiological factors mainly vitiate *Tridosha* (*Kapha* predominance associated *Pitta* vitiation and *Margavaranajanya* \[hindrance of function\] leading to provoking of *Vata)*. This *Tridosha* vitiation invites derangement of *Jatharagni* (digestive system), ultimately leading to the derangement of *Dhatvagni* (metabolic system) and subsequent appearance of *Ama*. This *Ama* blocks the channels in the body (*Srotorodha*), thereby afflicting the contents of channels causing vitiation of *Srotasa* as well as *Dhatu* to which these *Srotas* deliver.

The trial drug *Triphaladya Guggulu* is cited in *Yogaratnakara Gandamala Chikitsa* consists of *Guggulu* in combination with *Trikatu*, *Triphala* and *Kanchanara. Punarnava Guggulu* possesses digestive property to normalize excretory function, scraping of vitiated *Meda* with non-desirable *Dhatu* and *Vata-Kapha* pacification properties. *Trikatu* is known to have digestive and *Vata-Kapha* pacification properties. Digestive drugs prevent the formation of *Ama*, thereby preventing damage by keeping balanced state of digestion and metabolism. *Triphala* has *Tridosha* pacification properties and supports healthy digestion and absorption.

*Punarnavadi* decoction mentioned in *Chakradatta Shotha Chikitsa* contains *Punarnava*, *Devadaru* and *Shunthi* along with *Guggulu* as an adjuvents. The roots of *Punarnava* are claimed to possess diuretic and laxative\[[@ref12]\] properties and thus might have been functional in alleviating swelling, the most common presenting complaint. *Devadaru* possesses anti-inflammatory, immune-modulatory and diuretic properties.\[[@ref13]\] Vitamin C is an active component of *Devadaru*.\[[@ref13]\] Studies have shown that natural antioxidant therapy such as Vitamin C can reverse thyroid damage and prevent adverse effects to health by optimizing thyroid function.\[[@ref14]\] Moreover, *Devadaru* has *Lekhana* action. These properties of *Devadaru* might have helped in reducing weight.\[[@ref13]\] *Shunthi* owns digestive, pain-alleviating and *Vata-Kapha* pacification properties, preventing the formation of *Ama*. Preventing the formation of *Ama* can correct the pathogenesis at the beginning itself.

Few observations noted after the trial {#sec2-20}
--------------------------------------

Out of 15 registered patients, 86.66% had positive drug history for consumption of levothyroxine. After clinical trial, 6.66% of the patients continued their previous dosage of levothyroxine, while 80% of the patients had withdrawn their hormone replacement therapy. Not all the 80% of the patients who had withdrawn levothyroxine could restore normal thyroid profile, but they were quite satisfied with Ayurvedic management and were not willing to resume previously on-going synthetic thyroxin. These observations were noted 4 months after the completion of the clinical trial. An additional observation was that on long-term follow-up, thyroid profile showed a trend toward normalcy even in the cases that could not restore normal thyroid profile during the trial.

Conclusion {#sec1-5}
==========

Although any disease condition is not described in Ayurveda which is similar to hypothyroidism, it is found to possess a strong correlation with *Agnimandya* and *Ama*. The trial drugs showed highly significant results on subjective parameters. Vitiation of *Dhatvagni* once created cannot be corrected easily; hence, *Shamana* therapy should be administered for sufficient time to cure *Ama* at *Dhatu* level. From the clinical trial, it can be concluded that *Triphaladya Guggulu* and *Punarnavadi* decoction are effective in the management of hypothyroidism.
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